UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
 
Date of report (Date of earliest event reported): July 14, 2014
 
Applied DNA Sciences, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
  
002-90539
(Commission File Number)
  
59-2262718
(IRS Employer
Identification No.)
 
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of Principal Executive Offices) (Zip Code)
 
631-240-8800
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 40.14d - (b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e - (c))
 
 
 

 

 
Item 1.01.
Entry into a Material Definitive Agreement.
 
On July 14, 2014, Applied DNA Sciences, Inc. (the “Company”) was awarded a Phase II SBIR contract by the U.S. Missile Defense Agency (“MDA”) to perform research and development for avoidance of counterfeit parts by expanding the scope and scale of its existing SigNature DNA® technology platform established in its Phase I SBIR contract for Federal Supply Class 5962 electronic components, and by developing an optical reader.  The contract provides for monthly payments to the Company totaling approximately $975,000 over a two year period.
 
 
Item 8.01  Other Events.
 
A copy of the press release issued by the Company on July 15, 2014 relating to the SBIR Phase II contract is furnished as Exhibit 99.1 and is incorporated herein by reference.
 
 
Item 9.01 Financial Statements and Exhibits.
 
(d)           Exhibits.
 
 
10.1
99.1
Form of Award/Contract issued by U.S. Missile Defense Agency dated July 14, 2014.
Press Release issued by Applied DNA Sciences, Inc. on July 15, 2014.
 
 
 

 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Applied DNA Sciences, Inc.
 
(Registrant)
     
     
 
By:
/s/ James A. Hayward  
   
James A. Hayward
   
Chief Executive Officer
     
Date: July 18, 2014
 
 
 

 


EXHIBIT INDEX
 
Exhibit No.
  
Description
 
  
 
10.1
  
Form of Award/Contract issued  by U.S. Missile Defense Agency dated  July 14, 2014.
99.1
  
Press Release issued by Applied DNA Sciences on  July 15, 2014.